STAAR Surgical Company (STAA)

$111.58

+9.55 (+9.36%)
Rating:
Recommendation:
Buy
Symbol STAA
Price $111.58
Beta 1.084
Volume Avg. 0.44M
Market Cap 5.335B
Shares () -
52 Week Range 49.03-163.08
1y Target Est -
DCF Unlevered STAA DCF ->
DCF Levered STAA LDCF ->
ROE 10.48% Buy
ROA 5466.93% Strong Buy
Operating Margin -
Debt / Equity 25.63% Neutral
P/E 171.66 Strong Buy
P/B 17.85 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest STAA news


Ms. Caren Mason
Healthcare
Medical Instruments & Supplies
NASDAQ Global Market

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.